Work

Immune control of tumor stemness and therapy resistance

Year: 2026
Type: article
Abstract: Cancer stem cells (CSC) are a small group of tumor cells capable of self-renewing, giving rise to new tumors, and resisting treatment, thereby causing recurrence and metastasis and representing a serious clinical problem. However, there are no approved therapies for their elimination, and limited information is available on the effects of current therapies on tumor stemness. A general consensus suggests that the anti-inflammatory and immunosuppressive tumor microenvironment promotes tumor stemness. Since we previously reported that ablation of the p50 NF-κB gene in the hematopoietic compartment (p50fl/flTie2-Cre mice) restores M1/Th1 antitumor immunity, we studied its effects on CSC and therapy resistance in models of fibrosarcoma and melanoma. Using p50fl/flTie2-Cre mice, we demonstrate that p50 NF-κB silencing impairs CSC development, their migratory capacity, and epithelial-mesenchymal transition (EMT), events known to correlate with tumor aggressiveness. Furthermore, we identify a clear antagonistic effect between Th1 and Th2 T cell polarization, with the former acting as inhibitors and the latter promoting the stemness phenotype. Consistently, while immunotherapy with anti-PD-1 promoted a marked reduction in CSC and tumor development, associated with increased levels of IFNγ, whereas concomitant administration of anti-IFNγ antibodies restored tumor growth and dissemination. Moreover, treatment with anti-IL-4 enhanced the antitumor effects of immunotherapy, reducing tumor cell stemness. Importantly, the antitumor effects of high-dose IFNγ and anti-IL-4 were confirmed in combination with doxorubicin chemotherapy. Overall, our data indicate that shifting the immune response toward a robust M1/Th1 state can significantly improve current immunotherapies and chemotherapies, by limiting CSC properties.
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: hybrid
OpenAlex ID: W7236860969
FWCI:
Cites:
Cited by:
Related to: 10